Hosted on MSN1mon
Evercore ISI lifts CRISPR stock rating, target to $99
The new price target of $99 takes into account the potential of CRISPR Therapeutics' in vivo programs, CTX320 and CTX310. Evercore ISI has assigned a probability of success (POS) of 10% and 5% to ...
ETF Daily News11d
Evercore ISI Cuts Fortrea (NASDAQ:FTRE) Price Target to $15.00
Fortrea (NASDAQ:FTRE – Free Report) had its target price lowered by Evercore ISI from $20.00 to $15.00 in a research report sent to investors on Tuesday morning,Benzinga reports. The firm ...
Yahoo Finance26d
Evercore adds Wendy’s to outperform list ahead of investor day
Investing.com -- Evercore ISI added Wendy’s Co to its Tactical Outperform list ahead of the company’s investor day on March 6, citing discounted valuation, a potential industry turnaround ...
Investing9d
Evercore ISI lifts Canadian Natural stock rating to Outperform
On Friday, Evercore ISI analyst Stephen Richardson raised the rating for Canadian Natural Resources Limited (TSX:CNQ:CN) (NYSE: CNQ) from In Line to Outperform, while maintaining the price target ...
Evercore ISI Forecasts Strong Price Appreciation for Albertsons Companies (NYSE:ACI) Stock
Albertsons Companies (NYSE:ACI – Get Free Report) had its target price lifted by research analysts at Evercore ISI from $21.00 to $22.00 in a report issued on Tuesday,Benzinga reports. The brokerage ...
Yahoo Finance29d
CRISPR Therapeutics upgraded to Outperform by Evercore ISI
CRISPR Therapeutics (CRSP) shares jump after Evercore ISI upgraded the stock to Outperform from In Line. Julie Hyman and Josh Schafer examine what the analysts say about the biotech company on ...